← All trials
NCT03805100
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2019
- Primary completion
- May 31, 2020
- Completion date
- Feb 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 580
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xbrane Biopharma ABLead sponsor
- Tel Aviv UniversityOverall official - principal investigator
- STADA Arzneimittel AGCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.